Methods and Compositions for Modulating Angiogenesis and Vasculogenesis
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 15/063,290, filed Mar 7, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,245,286 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis In force · Medium confidence | Sanbio, Inc. | In force | Medium confidence | ||
| US 12,171,787 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis In force · High confidence | Sanbio, Inc. | In force | High confidence | ||
| US 11,304,982 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis In force · Medium confidence | Sanbio, Inc. | In force | Medium confidence | ||
| Application 13/750,772 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis Abandoned Abandoned May 25, 2016 | Sanbio, Inc. | Abandoned | Abandoned May 25, 2016 | ||
| Application 15/063,290 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis Abandoned Abandoned Nov 13, 2017 | Sanbio, Inc. | Abandoned | Abandoned Nov 13, 2017 | ||
| Application 18/941,420 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis Pending Not granted | Sanbio, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Sanbio, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.